WINREVAIR had previously received Breakthrough Therapy Designation from the FDA. It represents the first FDA-approved therapy targeting activin signaling inhibition for PAH, offering a novel ...

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Merck gained Winrevair in its $11.5 billion acquisition of Acceleron in 2021 and got it across the FDA finish line in March of 2024 based on results from the phase 3 STELLAR trial.

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study Merck (NYSE: MRK), known as MSD ...

The therapy, branded Winrevair, is already approved for treating the rare condition which causes high blood pressure in the lungs, leading to symptoms such as shortness of breath, chest pain and ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30, ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial hypertension functional class II or III at intermediate or ...